Patients with HR+, HER2–, Early Breast Cancer Experienced Survival Improvement with Verzenio Plus Endocrine Therapy

Findings from the monarchE trial presented at ASCO showed that for patients with hormone receptor–positive, HER2-negative, high-risk, early breast cancer, Verzenio provided “consistent treatment benefit.”

Related Keywords

United States ,Chicago ,Illinois ,San Antonio ,Texas ,American , ,Sarah Cannon Research Institute In Nashville ,San Antonio Breast Cancer Congress ,American Society Of Clinical Oncology Annual Meeting ,Clinical Oncology Annual Meeting ,Sarah Cannon Research Institute ,Antonio Breast Cancer Congress ,Asco 2023 ,Breast Cancer ,